Key result
Drug-eluting stents cut restenosis vs. bare-metal stents but raise early concerns for stent thrombosis.
Why the study?
Drug-eluting stents have been universally adopted despite limited on-label indications and early reports of stent thrombosis, necessitating a review of their safety and efficacy compared to bare-metal stents.
Do drug-eluting stents improve safety, efficacy, and mortality compared to bare-metal stents in patients undergoing PCI?
Do drug-eluting stents improve safety, efficacy, and mortality compared to bare-metal stents in patients undergoing PCI?
This review discusses the risk factors for stent thrombosis and compares outcomes between bare-metal and drug-eluting stents.
Drug-eluting stents reduce restenosis, particularly in uncomplicated lesions. Despite limited on-label indications, drug-eluting stents have been universally adopted. However, there have been early sporadic reports of stent thrombosis. This article will review the risk factors for stent thrombosis and will briefly discuss recent trials comparing the safety, efficacy, and mortality for bare-metal and drug-eluting stents.
No takes yet. Share an insight, caveat, or question.
George Wayne Vetrovec (2010) conducted a review in Patients undergoing PCI. Drug-eluting stents vs. Bare-metal stents was evaluated. Drug-eluting stents reduce restenosis but are associated with early sporadic reports of stent thrombosis, prompting a review of their safety and efficacy compared to bare-metal stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: